These findings emphasise that further analysis of the role of CD26 in immune modulation in breast cancer and tentatively suggest that the aggressive 4T1 tumours may build up a more immune suppressive environment, as compared to the less aggressive 4T07 tumours. This evidence concerns the gene DPP4 and breast carcinoma.